Nosocomial Infections - Pipeline Insight, 2024

This “Nosocomial Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Nosocomial Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nosocomial Infections Understanding

Nosocomial Infections: Overview

Nosocomial infections also referred to as healthcare-associated infections (HAI), are infection(s) acquired during the process of receiving health care that was not present during the time of admission. They may occur in different areas of healthcare delivery, such as in hospitals, long-term care facilities, and ambulatory settings, and may also appear after discharge. HAIs also include occupational infections that may affect staff. Infection occurs when pathogen(s) spread to a susceptible patient host. In modern healthcare, invasive procedures and surgery, indwelling medical devices, and prosthetic devices are associated with these infections. The etiology of HAI is based on the source or type of infection and the responsible pathogen, which may be bacterial, viral, or fungal.

HAI is the most common adverse event in health care that affects patient safety. They contribute to significant morbidity, mortality, and financial burden on patients, families, and healthcare systems. The emergence of multi-drug resistant organisms is another complication seen with HAI. HAI affects 3.2% of all hospitalized patients in the United States, 6.5% in the European Union/European Economic Area, and worldwide prevalence is likely much higher. The burden of HAIs worldwide is unknown owing to the lack of surveillance systems for HAIs. However, there has been a great effort by infection prevention and control programs to develop surveillance systems and infection control methods.

Nosocomial Infections - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nosocomial Infections pipeline landscape is provided which includes the disease overview and Nosocomial Infections treatment guidelines. The assessment part of the report embraces, in depth Nosocomial Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Nosocomial Infections R&D. The therapies under development are focused on novel approaches to treat/improve in Nosocomial Infections.
• In January 2021, Hoth Therapeutics announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command (USAMRDC) for a new molecular entity (NME) developed by the Walter Reed Army Institute of Research with a novel antibacterial mechanism of action that targets multiple bacterial pathogens. While this NME (to be developed under the identifier HT-006) has the potential to treat many different types of bacterial infections, Hoth will initially target treatment of serious bacterial infections of the lung, such as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

This segment of the Nosocomial Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nosocomial Infections Emerging Drugs

HT-006: Hoth TherapeuticsHT-006 is a new molecular entity (NME) developed by the Walter Reed Army Institute of Research with a novel antibacterial mechanism of action that targets multiple bacterial pathogens. While HT-006 has the potential to treat many different types of bacterial infections, Hoth will initially target treatment of serious bacterial infections of the lung, such as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

AR-301 (tosatoxumab): Aridis PharmaceuticalsAR-301 (tosatoxumab) is a fully human monoclonal IgG1 antibody (mAb) that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA).

AR-101: Aridis PharmaceuticalsAR-101 (AerumabTM) is a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11, which accounts for ~22% of all P. aeruginosa hospital-acquired infections worldwide. Binding of AR-101 to P. aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human phagocytes.

Nosocomial Infections: Therapeutic Assessment

This segment of the report provides insights about the different Nosocomial Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nosocomial Infections

There are approx. 15 key companies which are developing the therapies for Nosocomial Infections. The companies which have their Nosocomial Infections drug candidates in the most advanced stage, i.e. Phase III include Aridis Pharmaceuticals.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Nosocomial Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Monoclonal Antibody
• Anti-infectives

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nosocomial Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nosocomial Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nosocomial Infections drugs.

Nosocomial Infections Report Insights

• Nosocomial Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nosocomial Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nosocomial Infections drugs?
• How many Nosocomial Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nosocomial Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nosocomial Infections?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nosocomial Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hoth Therapeutics
• Helperby Therapeutics
• Clarametyx Biosciences
• Clarametyx Biosciences
• BioVersys
• Aridis Pharmaceuticals
• Merck & Co
• Key Products
• HY 012B5
• HT 006
• HY 015B12
• CMTX 101
• BV100
• AR-105
• AR-101
• Cefiderocol
• Tosatoxumab
• Tedizolid

This product will be delivered within 1-3 business days.